Dianthus Therapeutics Book Value Per Share Growth & History (DNTH)
Dianthus Therapeutics's book value per share was $11.42 for fiscal 2025.
View full Dianthus Therapeutics company overviewDianthus Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.42 | $0.09 | +0.77% |
| 2024 | 2024-12-31 | $11.33 | -$0.07 | −0.60% |
| 2023 | 2023-12-31 | $11.40 | $62.09 | — |
| 2022 | 2022-12-31 | -$50.69 | $273.17 | — |
| 2021 | 2021-12-31 | -$323.86 | -$3,597.34 | — |
| 2020 | 2020-12-31 | $3,273.48 | -$696.85 | −17.55% |
| 2019 | 2019-12-31 | $3,970.33 | -$857.64 | −17.76% |
| 2018 | 2018-12-31 | $4,827.96 | $24,603.97 | — |
| 2017 | 2017-12-31 | -$19,776.00 | $45,792.79 | — |
| 2016 | 2016-12-31 | -$65,568.80 | — | — |
Dianthus Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $21.39 | $11.97 | +127.07% |
| Q1 2026 | 2026-03-31 | $22.01 | $11.78 | +115.17% |
| Q4 2025 | 2025-12-31 | $11.42 | $0.09 | +0.77% |
| Q3 2025 | 2025-09-30 | $12.75 | $1.25 | +10.82% |
| Q2 2025 | 2025-06-30 | $9.42 | -$2.78 | −22.82% |
| Q1 2025 | 2025-03-31 | $10.23 | -$2.47 | −19.45% |
| Q4 2024 | 2024-12-31 | $11.33 | -$0.07 | −0.60% |
| Q3 2024 | 2024-09-30 | $11.51 | -$0.53 | −4.42% |
| Q2 2024 | 2024-06-30 | $12.20 | $1,130.91 | — |
| Q1 2024 | 2024-03-31 | $12.70 | $937.78 | — |
| Q4 2023 | 2023-12-31 | $11.40 | $62.09 | — |
| Q3 2023 | 2023-09-30 | $12.04 | $645.65 | — |
| Q2 2023 | 2023-06-30 | -$1,118.70 | -$602.73 | — |
| Q1 2023 | 2023-03-31 | -$925.08 | -$3,763.76 | — |
| Q4 2022 | 2022-12-31 | -$50.69 | $273.17 | — |
| Q3 2022 | 2022-09-30 | -$633.61 | -$4,196.47 | — |
| Q2 2022 | 2022-06-30 | -$515.98 | -$4,344.34 | — |
| Q1 2022 | 2022-03-31 | $2,838.67 | -$92.84 | −3.17% |
| Q4 2021 | 2021-12-31 | -$323.86 | -$3,597.34 | — |
| Q3 2021 | 2021-09-30 | $3,562.87 | -$61.99 | −1.71% |
| Q2 2021 | 2021-06-30 | $3,828.36 | -$151.66 | −3.81% |
| Q1 2021 | 2021-03-31 | $2,931.52 | -$577.39 | −16.46% |
| Q4 2020 | 2020-12-31 | $3,273.48 | -$696.85 | −17.55% |
| Q3 2020 | 2020-09-30 | $3,624.86 | -$954.38 | −20.84% |
| Q2 2020 | 2020-06-30 | $3,980.02 | -$1,140.76 | −22.28% |
| Q1 2020 | 2020-03-31 | $3,508.91 | -$896.41 | −20.35% |
| Q4 2019 | 2019-12-31 | $3,970.33 | -$857.64 | −17.76% |
| Q3 2019 | 2019-09-30 | $4,579.24 | -$749.76 | −14.07% |
| Q2 2019 | 2019-06-30 | $5,120.78 | -$660.10 | −11.42% |
| Q1 2019 | 2019-03-31 | $4,405.32 | — | — |
| Q4 2018 | 2018-12-31 | $4,827.96 | $24,603.97 | — |
| Q3 2018 | 2018-09-30 | $5,329.00 | — | — |
| Q2 2018 | 2018-06-30 | $5,780.88 | — | — |
| Q4 2017 | 2017-12-31 | -$19,776.00 | — | — |
Dianthus Therapeutics book value per share trends
Over the last five fiscal years, Dianthus Therapeutics's book value per share decreased from $3,273.48 to $11.42, a change of -$3,262.06. The latest reported quarter, Q2 2026, shows $21.39.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dianthus Therapeutics source filings ↗